Evaluating CMR

Metabolic Syndrome and Type 2 Diabetes/CVD Risk

NCEP-ATP III

Key Points

Page: Go to Previous Page 1 of 11 Go to Next Page

  • NCEP-ATP III guidelines have emphasized that the metabolic syndrome is a secondary target of therapy beyond elevated LDL cholesterol.
  • NCEP-ATP III guidelines have also singled out excess abdominal adipose tissue as a key feature of the metabolic syndrome.
  • Other elements of the metabolic syndrome include atherogenic dyslipidemia, insulin resistance, a pro-inflammatory and pro-thrombotic profile, and high blood pressure.
  • To date, numerous prospective studies have shown that the metabolic syndrome predicts CVD risk, with very few exceptions.
  • Overall CVD risk related to the metabolic syndrome has been evaluated in meta-analyses, which have concluded that the metabolic syndrome increases relative risk of CVD.
  • The metabolic syndrome is a stronger predictor of type 2 diabetes than CVD risk.